Entering text into the input field will update the search result below

AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity Picture

Sep. 17, 2023 3:52 AM ETAngioDynamics, Inc. (ANGO)7 Comments
Zach Bristow profile picture
Zach Bristow


  • AngioDynamics, Inc. posted mixed results in its FY'23 reports, with strong growth in its Med Tech division.
  • The company's focus going forward will be on its Med Tech segment, which has shown high growth and higher margins.
  • It's the economic performance that matters here, with investment and profitability trends drawn into question.
  • Net-net, reiterate hold.
New York Stock Exchange, Wall st, New York, USA

Matteo Colombo

Investment Briefing

AngioDynamics, Inc. (NASDAQ:ANGO) posted its fiscal '23 numbers last month, with mixed results. On the one hand, divisional growth was strong in Med Tech and parts of its mechanical thrombectomy lines. On the other, profitability didn't even attend the party, whereas investors

This article was written by

Zach Bristow profile picture
Strategist, global markets, at Bernard Holdings. Objective view on the directional bias of markets. Technical expertise bridges the complex relationships between value drivers, capital flows and price action. Clients are represented over the cross-section of financial markets, from speculators, hedgers, long-term traders and the public. Research covers investment securities and futures markets.Shoot me a message to talk trade ideas or portfolio construction. Disclaimer:All research is strictly for informational purposes only. Not to be considered investment advice. Please remember to conduct your own due diligence.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (7)

Anaconda Steel profile picture
Thoughts on 13d filing of >10% equity holding disclosure by Blackrock ? So they don’t grow, but an acquisition of this company will get a min 2x upto 3-4x market cap multiple range … “buy and hold” IMO
@Anaconda Steel my opinion is that Angiodynamics is a reasonably well managed business, but (due to competition from larger companies) ANGO achieves only moderate sales revenue growth. I am not aware of any catalyst that will dramatically increase revenues, so my best guess is that (depending on the overall stock market environment) ANGO stock price will trade in a range of $5 to $8 per share.
If a larger company were to acquire Angiodynamics my guess is that it would be for at least $15 per share.
Zach Bristow profile picture
@DGCO @Anaconda Steel both very fair and reasonable points. Re Blackrock's position, not sure on what to comment. It has stakes in so many companies that it begins to blur the lines on why they choose to own and not. Agree regarding the prospect of a buyout at $12–$15, but no clarity on who the buyer would be.
Anaconda Steel profile picture
@Zach Bristow agreed - who knows, they’re aren’t many mid-caps like this anymore most have been acquired by “the bigger med co’s”, I think they have a pathway to turn things around thus ‘buy and hold’ IMO
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About ANGO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ANGO

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.